Analyst firms · Barclays · EXEL

Barclays EXEL price target and rating history

Exelixis Inc. (EXEL) · Health Care

Barclays rates Exelixis Inc. (EXEL) Equal Weight with a $40 price target, as of its latest action on Sep 19, 2025. It has published 3 rating actions on EXEL since April 2024, including 0 upgrades and 1 downgrade. Across 5 firms with a EXEL price target in the last 12 months, the median target is $52.

Current rating

Equal Weight

Price target

$40

Median target, all firms

$52

Actions on EXEL

3

Barclays price target on EXEL

Every Barclays rating on EXEL

• Sep 19, 2025
  ResumeBarclays resumes coverage at Equal Weight, price target $40
• Sep 17, 2025
  ResumeBarclays resumes coverage at Equal Weight, price target $40
• Apr 11, 2024
  DowngradeBarclays downgrades to Equal Weight from Overweight, price target $25

How other firms rate EXEL

Each firm's latest rating and stated target in the last 12 months.

Questions about Barclays and EXEL

What is Barclays's price target for EXEL?

Barclays's latest stated price target for Exelixis Inc. (EXEL) is $40, from its action on Sep 19, 2025.

What is Barclays's rating on EXEL?

Barclays rates EXEL Equal Weight, a neutral rating, as of Sep 19, 2025.

When did Barclays last change its view on EXEL?

On Sep 19, 2025, Barclays resumes coverage at Equal Weight, price target $40.

How does Barclays's EXEL target compare with other analysts?

Across 5 firms with a EXEL price target in the last 12 months, the median target is $52.

More EXEL rating histories

• BMO Capital Markets3
• Leerink Partners3
• Morgan Stanley3
• RBC Capital Markets3
• Oppenheimer3
• H.C. Wainwright4

All Barclays ratingsEXEL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.